Extension usage examples:
Here's how our browser extension sees the article:
Tumour therapy with radionuclides: assessment of progress and problems - ScienceDirect
Source: sciencedirect.com
Article summary:
1. Radionuclide therapy is a promising modality for treating tumours of haematopoietic origin, but has had limited success in treating solid tumours.
2. New knowledge related to radionuclide therapy is emerging, including improved understanding of the factors of importance for the choice of appropriate radionuclides and new methods to modify uptake of radionuclides in tumour cells and normal tissues.
3. Improvements are still needed regarding dosimetry and treatment planning, as well as an increased knowledge about the tolerance doses for normal tissues and radiobiological effects on tumour cells.
Article analysis:
This article provides an overview of the progress made in radionuclide therapy for treating tumours, with a focus on haematopoietic origin. The authors provide a comprehensive review of the current state-of-the-art in this field, discussing topics such as decreased radionuclide uptake in normal tissues, improved uptake in tumour cells, principles for new targeting agents and their pharmacokinetics, genomic instability, future targets, choice of radionuclides, improved dosimetry and treatment planning, radiobiology and availability of radiopharmaceuticals.
The article appears to be written by experts in the field who have conducted extensive research into this topic. The authors provide detailed information on each topic discussed and cite relevant sources throughout the article. The article does not appear to be biased or one-sided; rather it presents both sides equally by providing an overview of both successes and challenges associated with radionuclide therapy. Furthermore, potential risks are noted throughout the article which suggests that safety is taken seriously by the authors.
In conclusion, this article appears to be reliable and trustworthy due to its comprehensive coverage of topics related to radionuclide therapy as well as its lack of bias or one-sided reporting.